Researchers identify 18F-PMSA-1007 as an equally effective radiopharmaceutical for detecting prostate cancer.
Molecular imaging technique performs better with detection, staging, and determining treatment plans.
The imaging process provides the most time-efficient sequence with the highest lesion detection rate and conspicuity.
Thirty-two men participated in the retrospective study.
Coverage for prostate MRIs results in challenges for patients and referring physicians seeking to obtain ready access.
Despite undergoing more imaging outside the VA system, men with low-risk prostate cancer don’t show an improvement in care quality.
PSA-density does not appear to significantly improve its diagnostic performance.
A structured template for PI-RADS may increase the diagnostic performance of prostate MRI for clinically significant prostate cancer.
MR imaging of the prostate detects more treatable cancers and reduces overdiagnosis than standard ultrasound-guided biopsies.
Three-dimensional imaging could provide equivalent image quality to 2D acquisitions in T2-weighted imaging of the prostate at 3T.